Sareum Holdings PLC
RYH0
Company Profile
Business description
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
Contact
Langford Arch, London Road
Unit 2a, Pampisford
CambridgeCambridgeshireCB22 3FX
GBRT: +44 1223497700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
5
Stocks News & Analysis
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Shares fell as investors digested the latest earnings.
stocks
Two new ASX names added to our Global Best Stock Ideas
Our full global list includes 78 companies from around the world.
stocks
Big four bank holds up in weakening economic conditions
Major bank earnings hold up in challenging conditions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,972.30 | 36.60 | -0.41% |
| CAC 40 | 8,020.31 | 27.38 | -0.34% |
| DAX 40 | 25,864.62 | 116.47 | -0.45% |
| Dow JONES (US) | 51,786.72 | 197.26 | -0.38% |
| FTSE 100 | 10,638.43 | 122.90 | -1.14% |
| HKSE | 23,525.97 | 132.65 | 0.57% |
| NASDAQ | 25,372.01 | 207.65 | 0.83% |
| Nikkei 225 | 62,899.21 | 182.65 | -0.29% |
| NZX 50 Index | 13,738.03 | 17.77 | 0.13% |
| S&P 500 | 7,568.92 | 27.52 | 0.36% |
| S&P/ASX 200 | 8,844.30 | 42.50 | -0.48% |
| SSE Composite Index | 3,608.10 | 29.93 | -0.82% |